# Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

> **NCT03631732** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 496 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** B/F/TAF
- **DRUG:** NRTIs
- **DRUG:** Third Agent

## Key facts

- **NCT ID:** NCT03631732
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-28
- **Primary completion:** 2019-08-12
- **Final completion:** 2020-08-19
- **Target enrollment:** 496 (ACTUAL)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631732, "Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03631732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*